FDA Commissioner Margaret A. Hamburg’s Statement on the 50th Anniversary Surgeon General’s Report on Smoking and Health
For Immediate Release: Jan. 17, 2014 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm382100.htm
Leggi
The Health Consequences of Smoking – 50 Years of Progress: A Report of the Surgeon General
http://www.surgeongeneral.gov/library/reports/50-years-of-progress/index.html
Leggi
FDA alerts companies to stop illegal sale of treatments for diabetes
Includes certain products containing undeclared active pharmaceutical ingredients FDA NEWS RELEASE July 23, 2013 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm362012.htm
Leggi
European Medicines Agency – Investigation into GLP-1 based diabetes therapies concluded
No new concerns for GLP-1 therapies identified on the basis of available evidence. 26/07/2013 EMA Press release http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001856.jsp&mid=WC0b01ac058004d5c1
Leggi
Fluoroquinolone Antibacterial Drugs: Drug Safety Communication- Risk for possibly permanent nerve damage
FDA Safety [Posted 08/15/2013] http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm365302.htm
Leggi
Testosterone Products: Drug Safety Communication – FDA Investigating Risk of Cardiovascular Events
01/31/2014 - Drug Safety Communication - FDA http://www.fda.gov/Drugs/DrugSafety/ucm383904.htm
Leggi
European Medicines Agency – PRAC recommends using acipimox only as additional or alternative treatment to lower high triglyceride levels.
08/11/2013 EMA Press release http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/11/WC500154014.pdf
Leggi
Le nuove norme per la rimborsabilità a carico del SSN dei farmaci agenti sul sistema delle incretine
Nuove norme per la rimborsabilità a carico del SSN dei farmaci agenti sul sistema delle incretine: - Obbligo di piano terapeutico web-based per tutti - Nuove norme sulla rimborsabilità legate ai valori di Hb glicata attuali e ai target - Esclusione dalla rimborsabilità della monoterapia con l'eccezione…
Leggi
U.S. Food and Drug Administration
Statin Drugs - Drug Safety Communication: Class Labeling Change 28/02/2012 http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm293670.htm
Leggi
Nota informativa importante concordata con l’Agenzia Europea dei Medicinali (EMA) e l’Agenzia Italiana del Farmaco (AIFA) – 8 marzo 2012
Comunicazione agli operatori sanitari su gravi reazioni di ipersensibilità e di pancreatite acuta associate all’uso di saxagliptin (Onglyza) http://www.agenziafarmaco.gov.it/it/content/nota-informativa-importante-su-onglyza-saxagliptin-08032012
Leggi